Nexalin Technology Inc. (NXL)
NASDAQ: NXL
· Real-Time Price · USD
0.91
-0.01 (-1.02%)
At close: Oct 03, 2025, 3:59 PM
0.91
0.14%
After-hours: Oct 03, 2025, 06:18 PM EDT
-1.02% (1D)
| Bid | 0.9 |
| Market Cap | 15.85M |
| Revenue (ttm) | 174.81K |
| Net Income (ttm) | -8.85M |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | -1.18 |
| Forward PE | -2.36 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.95 |
| Volume | 93,869 |
| Avg. Volume (20D) | 1,012,653 |
| Open | 0.91 |
| Previous Close | 0.92 |
| Day's Range | 0.89 - 0.92 |
| 52-Week Range | 0.59 - 4.49 |
| Beta | 3.64 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for NXL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNexalin Technology Inc. is scheduled to release its earnings on
Nov 7, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-25.7%
Nexalin Technology shares are trading lower after ...
Unlock content with
Pro Subscription
11 months ago
+26.91%
Nexalin Technology shares are trading higher after the company announced it regained listing requirements compliance with Nasdaq.
1 year ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...
